Aligos Therapeutics Inc. (ALGS) Announces James Scopa to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- S&P 500, Nasdaq futures slip after tech rally; Warsh's speech awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
April 27, 2021 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Companys board of directors.
We are thrilled to add someone of Jims experience and accomplishments to Aligos board, as the company continues its arc from its earliest, private, preclinical phase to growing into its role as an established clinical-stage public biopharma company, said... More
